Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3657511 | 0.98 | HRH3 (0.47) | HRH3KCNH2KDM2BHTR2AHTR2C | |
| SCHEMBL3658614 | 0.97 | HRH3 (0.46) | HRH3KCNH2KDM2BHTR2AHTR2C | |
| SCHEMBL3654015 | 0.87 | HRH3 (0.51) | HRH3KCNH2HTR2AHTR2CHTR2B | |
| SCHEMBL3656466 | 0.84 | HRH3 (0.49) | HRH3KCNH2HTR2AHTR2CHTR2B | |
| SCHEMBL3648862 | 0.84 | HTR2A (0.48) | HRH3KCNH2HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL3810162 | 0.83 | HRH3 (0.48) | HRH3KCNH2HTR2AHTR2CHTR2B | |
| SCHEMBL3654157 | 0.83 | USP30 (0.44) | HRH3KCNH2HTR2AHTR2CHTR2B | |
| SCHEMBL3653940 | 0.83 | HRH3 (0.48) | HRH3KCNH2HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL3657483 | 0.83 | HTR2A (0.47) | HRH3KCNH2HTR2AHTR2CHTR2B | |
| SCHEMBL3657719 | 0.83 | HRH3 (0.47) | HRH3KCNH2HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101842366-A | Azacyclylisoquinolinone and azacyclylisoindolone derivatives as histamine-3 antagonists | WYETH CORP | 2010-09-22 | — | — | CN | claimed |
| EP-2200998-A1 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009036117-A1 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-19 | — | — | WO | claimed |
| US-20090069370-A1 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-12 | — | — | US | claimed |
| CN-101842366-A | Azacyclylisoquinolinone and azacyclylisoindolone derivatives as histamine-3 antagonists | WYETH CORP | 2010-09-22 | — | — | CN | disclosed |
| EP-2200998-A1 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009036117-A1 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090069370-A1 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069370-A1 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH1, HRH2 | HRH3 4/4885KCNH2 456/4885KDM2B 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.